PharmAust has received a tidy $672,250 R&D tax refund from the Australian Government for its expenditure on the development of its flagship Monepantel anti-cancer drug. This includes work on its successful clinical trials and reformulating a high dose tablet with improved taste. The refund will be used to advance the company’s clinical trial programs in dogs and humans.
Related Data & Insights
-
-
Rank Company Revenue th PharmAust $842k 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX